导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 16.76% | 524/4773 |
| 近一周 | -0.21% | 972/5465 |
| 近一月 | 6.17% | 36/5421 |
| 近一季 | 7.54% | 228/5231 |
| 近半年 | 19.64% | 219/4920 |
| 近一年 | 23.86% | 364/4394 |
| 近两年 | 84.55% | 788/2954 |
| 近三年 | 110.41% | 123/2253 |
| 成立以来 | 56.51% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.65% 1489/4961 |
-0.11% 3250/5312 |
- - |
- - |
| 2025 | 32.27% 1188/4813 |
10.06% 347/3635 |
11.40% 186/4076 |
-0.61% 3933/4524 |
8.55% 240/4813 |
| 2024 | 36.99% 47/3463 |
3.80% 510/2808 |
14.97% 6/3014 |
4.08% 2907/3129 |
10.29% 280/3463 |
| 2023 | 0.56% 405/2656 |
-0.19% 1782/2280 |
6.87% 38/2385 |
-6.22% 1457/2515 |
0.53% 142/2655 |
| 2022 | 4.77% 21/2207 |
8.74% 14/1919 |
0.27% 1567/2016 |
-11.82% 592/2113 |
8.97% 245/2208 |
| 2021 | 3.87% 599/1822 |
13.28% 9/1255 |
-3.70% 1250/1330 |
-5.04% 766/1466 |
0.26% 1150/1822 |
| 2020 | -17.74% 1007/1250 |
-11.19% 822/1028 |
-3.82% 1040/1067 |
-16.24% 1137/1164 |
14.96% 241/1184 |
| 2019 | - - |
- - |
- - |
-4.63% 781/850 |
6.20% 643/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 泰康香港银行指数C VS. 长安沪深300非周期A(740101) |